scholarly journals A RETROSPECTIVE STUDY OF THE TREATMENT RESULTS OF 40 DIVERSE PATIENTS OF ANEMIA

2021 ◽  
Author(s):  
George Zhu
Keyword(s):  
Complete Remission ◽  
Peer Review ◽  
Hemolytic Anemia ◽  
Iron Status ◽  
Megaloblastic Anemia ◽  
Deficiency Anemia ◽  
Drug Induced ◽  
Effective Prevention ◽  
Immune Hemolytic Anemia

Background and objective: Anemia is clinical common event. There are many types of anemias, which included stem cell problems, vitamin deficiency, chronic diseases and drug antibody -induced immune hemolytic anemia. In this study, a retrospective purpose was investigated to assess the clinical efficacy of treatment and their outcome. Methods: Total 40 patients with different types of anemias were presented in the second affiliated hospital of central south University, China and my tumor institute during 1989-2019. The therapeutically design among those patients with anemias was setted to the various regimen according to diseases diagnoses. Results and conclusion: Total 23 patients achieved cure or complete remission (CR), with the exception of refractory cancers and uremic anemia. Iron supplement was provided in 5 iron deficiency anemia. One megaloblastic anemia produced an excellent response following the supplement of vitamin B12 and folic acid. 2 aplastic anemia obtained complete remission with the integrated protocol of methyl testosterone, adenine, leucogen, and levamisol. Steroid hormone (e.g. prednisone) mixed traditional medicine were occasionally promising benefit in a nephrotic syndrome and renal insufficiency. Among 2 cases with drug-induced immune hemolytic anemia (DIIHA), laboratory studies one patient's serum contained paracetamol-dependent antibody that in the presence of paracetamol, agglutinated in-vitro with "O" red cells with or without complement. Drug antibody titer was 1:4 positive. Immune hemolysis was mediated by both the immune complex and uptake of drugs, whereas hemolysis induced by another native herb was caused by absorption of the drug only. In addition, with respect to anemia induced by malignancies, the molecular genomic regulation of retinoic acid in APL has been elucidated (see illustration in full text). Therefore, promoting effective prevention and / or early preventive treatment of anemia is our concern.                    Peer Review History: Received 5 March 2021; Revised 27 March; Accepted 23 April, Available online 15 May 2021 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.  Received file:                Reviewer's Comments: Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 7.0/10 Reviewer(s) detail: Dr. Bilge Ahsen KARA,  Ankara Gazi Mustafa Kemal Hospital, Turkey, [email protected] Prof. Dr. Hassan A.H. Al-Shamahy,  Sana'a University, Yemen, [email protected] Similar Articles: THE ASSOCIATION BETWEEN LEVELS OF HEPCIDIN, IRON STATUS AND MICRO-INFLAMMATION MARKERS AMONG HAEMODIALYSIS

scholarly journals Retrospective Survey on the Outcome of 36 Diverse Cases of Anemia

2020 ◽  
Vol 1 (1) ◽  
pp. 01-07
Author(s):  
George Zhu
Keyword(s):  
Complete Remission ◽  
Megaloblastic Anemia ◽  
Molecular Genetic ◽  
Genetic Regulation ◽  
Deficiency Anemia ◽  
Comprehensive Treatment ◽  
Malignant Tumours ◽  
Drug Adsorption ◽  
Immune Hemolytic Anemia

Anemia is clinical common event. In this study,a retrospective study of 36 different types of anemias was place in proper interpretative review for their therapeutical outcome. By using comprehensive treatment regimen according to patients’ condition, 23 patients obtained cure or complete remission (CR), with the exception of refractory cancers and uremic anemia. Iron supplement was provided in 5 iron deficiency anemia. One megaloblastic anemia required the prescription of the supplement of vitamin B12 or folate deficiency. 2 aplastic anemia obtained complete remission with the integrated protocol of methyltestosterone,adenine,leucogen,and levamisol. Steroid hormone (e.g. prednisone) mixed traditional medicine were occasionally promising benefit in a nephrotic syndrome and renal insufficiency. Among 2 cases with dug- induced immune hemolytic anemia (DIIHA), laboratory studies a patient's serum contained paracetamol -dependent antibody that in the presence of paracetamol, agglutinated in vitro with "O" red cells with or without complement. Drug antibody titer was 1:4 positive. The reactive mechanism was attributed to both immune complex type and drug-adsorption, whereas another herba origanum vulgare- induced hemolysis secondary to drug adsorption only. In addition, regarding anemia caused by malignant tumours, the molecular genetic regulation of retinoic acid in acute promyelocytic leukemia (APL) has been further illustrated(see figure in full text). Therefore,to strengthen the active prevention and/or early interceptive treatment of anemia is our care.

scholarly journals Drug-induced immune hemolytic anemia

Hematology ◽  
2009 ◽  
Vol 2009 (1) ◽  
pp. 73-79 ◽  
Author(s):  
George Garratty
Keyword(s):  
Membrane Proteins ◽  
Hemolytic Anemia ◽  
Drug Induced ◽  
Serological Tests ◽  
Laboratory Findings ◽  
Rbc Membrane ◽  
Immune Hemolytic Anemia ◽  
Drug Dependent

Abstract Drug-induced immune hemolytic anemia (DIIHA) is rare, and a specialized laboratory is often required to provide the optimal serological tests to confirm the diagnosis. The most common drugs associated with DIIHA and the hypotheses for the mechanisms thought to be involved have changed during the last few decades. The drugs most frequently associated with DIIHA at this time are cefotetan, ceftriaxone, and piperacillin. DIIHA is attributed most commonly to drug-dependent antibodies that can only be detected in the presence of drug (eg, cephalosporin antibodies). DIIHA can also be associated with drug-independent antibodies; such antibodies do not need drug to be present to obtain in vitro reactions (eg, fludarabine). In these latter cases, the drug affects the immune system, causing production of red cell (RBC) autoantibodies; the clinical and laboratory findings are identical to autoimmune hemolytic anemia (AIHA), other than the remission associated with discontinuing the drug. Some of the mechanisms involved in DIIHA are controversial. The most acceptable one involves drugs, like penicillin, that covalently bind to proteins (eg, RBC membrane proteins); RBCs become coated with drug in vivo and, a drug antibody (usually IgG) attaches to the drug-coated RBCs that are subsequently cleared by macrophages. The most controversial is the so-called immune complex mechanism, which has been revised to suggest that most drugs are capable of binding to RBC membrane proteins, but not covalently like penicillins. The combined membrane plus drug can create an immunogen; the antibodies formed can be IgM or IgG and often activate complement, leading to acute intravascular lysis and sometimes renal failure; fatalities are more common in this group. It is still unknown why and how some drugs induce RBC autoantibodies, sometimes causing AIHA.

scholarly journals Drug-induced immune hemolytic anemia (Direct Antiglobulin Test positive)

2013 ◽  
Vol 69 (2) ◽  
pp. 190-192 ◽  
Author(s):  
R.S. Sarkar ◽  
J. Philip ◽  
R.S. Mallhi ◽  
Neelesh Jain
Keyword(s):  
Hemolytic Anemia ◽  
Direct Antiglobulin Test ◽  
Drug Induced ◽  
Immune Hemolytic Anemia ◽  
Antiglobulin Test

scholarly journals Drug-induced immune hemolytic anemia because of efavirenz

AIDS ◽  
2020 ◽  
Vol 34 (2) ◽  
pp. 326-328 ◽  
Author(s):  
Kyaw S. Lin ◽  
Sein Win ◽  
Phyo P. Nyein
Keyword(s):  
Hemolytic Anemia ◽  
Drug Induced ◽  
Immune Hemolytic Anemia

Immune hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma

Transfusion ◽  
2014 ◽  
Vol 54 (11) ◽  
pp. 2901-2905 ◽  
Author(s):  
Marisol Betensky ◽  
Char Witmer ◽  
Michael J. Fisher ◽  
Sandra Nance ◽  
Mitchell J. Weiss ◽  
...  
Keyword(s):  
Pediatric Patient ◽  
Hemolytic Anemia ◽  
Optic Pathway Glioma ◽  
Optic Pathway ◽  
Drug Induced ◽  
Immune Hemolytic Anemia

scholarly journals Ibuprofen-Induced Hemolytic Anemia

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Aram Barbaryan ◽  
Chioma Iyinagoro ◽  
Nwabundo Nwankwo ◽  
Alaa M. Ali ◽  
Raya Saba ◽  
...  
Keyword(s):  
Hemolytic Anemia ◽  
Blood Count ◽  
Complete Blood Count ◽  
Rare Condition ◽  
Shortness Of Breath ◽  
Drug Induced ◽  
Immune Hemolytic Anemia ◽  
Patient Reported ◽  
Mucous Membranes ◽  
New Onset

Drug-induced immune hemolytic anemia is a rare condition with an incidence of 1 per million of the population. We report the case of a 36-year-old female who presented to the emergency department complaining of shortness of breath and dark colored urine. Physical examination was significant for pale mucous membranes. The patient reported using ibuprofen for a few days prior to presentation. Complete blood count performed before starting ibuprofen revealed normal platelets and hemoglobin values. On admission, the patient had evidence of hemolytic anemia with hemoglobin of 4.9 g/dL, hematocrit of 14.2%, lactate dehydrogenase 435 IU/L, and reticulocytosis 23.2%. Further testing ruled out autoimmune disease, lymphoma, and leukemia as etiologies for the patient’s new onset hemolytic anemia. Ibuprofen was immediately stopped with a gradual hematologic recovery within 3 days.

Sign in / Sign up

Export Citation Format

Share Document